Trends in human immunodeficiency virus seroincidence among street-recruited injection drug users in San Francisco, 1987-1998

American Journal of Epidemiology

Volumn 157, Issue 10, 2003, Pages 915-922

  Kral, Alex H ^a   Lorvick, Jennifer ^a   Gee, Lauren ^a   Bacchetti, Peter ^a   Rawal, Bhupat ^b   Busch, Michael ^b   Edlin, Brian R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Blood Centers of the Pacific   (United States)

Author keywords

Adolescence; HIV; Homosexuality, male; Incidence; Risk factors; Sex behavior; Substance abuse, intravenous

Indexed keywords

DISEASE PREVALENCE; DRUG USER; HOMOSEXUALITY; HUMAN IMMUNODEFICIENCY VIRUS; SEXUAL BEHAVIOR;

ARTICLE; CALCULATION; CONFIDENCE INTERVAL; ENZYME IMMUNOASSAY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; INJECTION; LOGISTIC REGRESSION ANALYSIS; PREVALENCE; RISK FACTOR; SEROLOGY; SEXUAL BEHAVIOR; SUBSTANCE ABUSE;

ADULT; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; RISK FACTORS; SAN FRANCISCO; SENSITIVITY AND SPECIFICITY; SEROEPIDEMIOLOGIC STUDIES; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASES; SUBSTANCE ABUSE, INTRAVENOUS; URBAN HEALTH;

UNITED STATES;

EID: 0038217089     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/kwg070     Document Type: Article

References (41)

1. Nelson KE, Vlahov D, Solomon L, et al. Temporal trends of human immunodeficiency virus infection in a cohort of injecting drug users in Baltimore, MD. Arch Intern Med 1995;155: 1305-11.
2. Des Jarlais DC, Marmor M, Friedman P, et al. HIV incidence among injection drug users in New York City, 1992-1997: evidence for a declining epidemic. Am J Public Health 2000;90: 352-9.
3. Moss AR, Vranizan K, Gorter R, et al. HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. AIDS 1994;8:223-31.
4. Wiebel WW, Jimenez A, Johnson W, et al. Risk behavior and HIV seroincidence among out-of-treatment injection drug users: a four year prospective study. J Acquir Immune Defic Syndr 1996;12:282-9.
5. Friedman SR, Jose B, Deren S, et al. Risk factors for human immunodeficiency virus seroconversion among out-of-treatment drug injectors in high and low seroprevalence cities. Am J Epidemiol 1995;142:864-74.
6. Fisher DG, Fenaughty AM, Trubatch B. Seroconversion issues among out-of-treatment injection drug users. J Psychoactive Drugs 1998;30:299-305.
7. Holmberg SD. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health 1996;86:642-54.
8. Kral AH, Bluthenthal RN, Booth RE, et al. HIV seroprevalence among street-recruited injecting drug and crack cocaine users in 16 U.S. municipalities. Am J Public Health 1998;88:108-13.
9. Janssen RS, Satten GA, Stramer SL, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 1998;280:42-8.
10. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research: principles and quantitative methods. New York, NY: Van Nostrand Reinhold, 1982.
11. Kral AH, Bluthenthal RN, Lorvick J, et al. Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet 2001;357:1397-401.
12. Watters JK, Biernacki P. Targeted sampling: options for the study of hidden populations. Soc Probl 1989;36:416-30.
13. Watters JK, Estilo MJ, Clark GL, et al. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. JAMA 1994;271:115-20.
14. Interpretation and use of the Western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. MMWR Morb Mortal Wkly Rep 1989;38(no. S-7):1-7.
15. Satten GA, Janssen R, Busch MP, et al. Validating marker based incidence estimates in repeatedly screened populations. Biometrics 1999;55:1224-7.
16. D'Agostino RB, Lee ML, Belanger AJ, et al. Relation of pooled logistic regression to time dependent Cox regression analysis: The Framingham Heart Study. Stat Med 1990;9:1501-15.
17. Kral AH, Bluthenthal RN, Erringer EA, et al. Risk factors among IDUs who give injections to or receive injections from other drug users. Addiction 1999;94:675-83.
18. Watters JK. Trends in risk behaviors and HIV seroprevalence in heterosexual injection drug users in San Francisco, 1986-1992. J Acquir Immune Defic Syndr 1994;7:1276-81.
19. Des Jarlais DC. Harm reduction: a framework for incorporating science into drug policy. Am J Public Health 1995;85:10-12.
20. Kral AH, Lorvick J, Edlin BR. Sex- and drug-related risk among populations of younger and older injection drug users in adjacent neighborhoods in San Francisco. J Acquir Immune Defic Syndr 2000;24:162-7.
21. Doherty MC, Garfein RS, Monterroso E, et al. Correlates of HIV infection among young adult short-term injection drug users. AIDS 2000;14:717-26.
22. Garfein RS, Vlahov D, Galai N, et al. Viral infections in short-term injection drug users: the prevalence of the hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996;86:655-61.
23. Thorpe LE, Bailey SL, Huo DZ, et al. Injection-related risk behaviors in young urban and suburban injection drug users in Chicago (1997-1999). J Acquir Immune Defic Syndr 2001;27:71-8.
24. Hahn JA, Page-Shafer K, Lum P, et al. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology 2001;34:180-7.
25. Strathdee SA, Galai N, Safaiean M, et al. Sex differences in risk factors for HIV seroconversion among injection drug users: a 10-year perspective. Arch Intern Med 2001;161:1281-8.
26. Kellogg TA, McFarland W, Perlman JL, et al. HIV incidence among repeat HIV testers at a county hospital, San Francisco, California, USA. J Acquir Immune Defic Syndr 2001;28:59-64.
27. National Institutes of Health. Interventions to prevent HIV risk behaviors. (NIH Consensus Development Conference Statement, vol 15, no. 2). Bethesda, MD: National Institutes of Health, 1997:1-41.
28. Normand J, Vlahov D, Moses LE. Preventing HIV transmission: the role of sterile needles and bleach. Washington, DC: National Academy Press, 1995.
29. Kaplan EH, Khoshnood K, Heimer R. A decline in HIV-infected needles to New Haven's needle exchange program: client shift or needle exchange? Am J Public Health 1994;84:1991-4.
30. Holtgrave DR, Valdiserri RO, Gerber AR, et al. Human immunodeficiency virus counseling, testing, referral, and partner notification services: a cost-benefit analysis. Arch Intern Med 1993;153:1225-30.
31. Botwinick G, Douglas W, Johnson R, et al. Lessons learned: providing age-appropriate HIV service to adolescents. Rockville, MD: Health Resources and Services Administration, US Department of Health and Human Services, 2001:211-20.
32. Des Jarlais DC, Friedman SR, Friedman P, et al. HIV/AIDS related behavior change among injecting drug users in different national settings. AIDS 1995;9:611-17.
33. He H, Stark M, Fleming D, et al. The effects of HIV counseling and testing among out-of-treatment injection drug and crack users. Presented at the XI International Conference on AIDS, Vancouver, British Columbia, Canada, July 7-12, 1996.
34. Valdiserri RO, Moore M, Gerber AR, et al. A study of clients returning for counseling after HIV testing: implications for improving rates of return. Public Health Rep 1993;108:12-18.
35. Kegeles SM, Hays RB, Coates TJ. The Mpowerment Project: a community HIV prevention intervention for young gay men. Am J Public Health 1996;86:1129-36.
36. Kelly JA, Murphy DA, Sikkema KJ, et al. Randomised, controlled, community-level HIV-prevention intervention for sexual-risk behaviour among homosexual men in US cities. Community HIV Prevention Research Collaborative. Lancet 1997;350:1500-5.
37. McFarland W, Busch MP, Kellogg TA, et al. Detection of early HIV infection and estimation of HIV incidence using a sensitive/less sensitive testing strategy at anonymous counseling and testing sites in San Francisco. J Acquir Immune Defic Syndr Hum Retrovirol 1999;22:484-9.
38. Huang KH, Watters JK, Case P. Psychological assessment and AIDS research with intravenous drug users: challenges in measurement. J Psychoactive Drugs 1988;20:191-5.
39. Dowling-Guyer S, Johnson ME, Fisher DG, et al. Reliability of drug users' self-reported HIV risk behaviors and validity of self-reported recent drug use. Assessment 1994;1:383-92.
40. Watters JK, Needle R, Brown BS, et al. The self-reporting of cocaine use. (Letter). JAMA 1992;268:2374-5.
41. Weatherby N, Needle R, Cesari H, et al. Validity of selfreported drug use among injection drug users recruited through street outreach. Eval Program Plann 1994;17:347-55.